Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Capecitabine impairment

Capecitabine is used for the treatment of colorectal and breast cancers. It is contraindicated in patients with known hypersensitivity to capecitabine or any of its components or to 5-fluorouracil and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. The use of capecitabine is restricted in patients with severe renal impairment. The drag can induce diarrhea, sometimes severe. Other side effects include anemia, hand-foot syndrome, hyperbilirubinemia, nausea, stomatitis, pyrexia, edema, constipation, dyspnea, neutropenia, back pain, and headache. Cardiotoxicity has been observed with capecitabine. A clinically important drag interaction between capecitabine and warfarin has been demonstrated. Care should be exercised when the drag is co-administered with CYP2X9 substrates. [Pg.150]

These equations make a number of assumptions and may be used to estimate Mrs RP s renal function this is necessary as toxicity from capecitabine can be increased in individuals with renal impairment (creatinine clearance <50 mL/min). [Pg.212]

Her estimated creatinine clearance is 74 mL/min. This represents a relatively normal renal function, particularly for someone of Mrs RP s age. The Summary of Product Characteristics for capecitabine (Summary of Product Characteristics, 2008) states that the dosage only needs to be reduced if creatinine clearance is between 30 and 50 mL/min, to 75% dosage. If creatinine clearance is <30 mL/min, then capecitabine is contraindicated. This is because the incidence of severe adverse effects is more common in patients with renal impairment compared with the overall population. [Pg.213]


See other pages where Capecitabine impairment is mentioned: [Pg.252]    [Pg.255]    [Pg.255]    [Pg.475]    [Pg.1812]   
See also in sourсe #XX -- [ Pg.213 ]




SEARCH



Capecitabin

Impaired

Impairment

© 2024 chempedia.info